For many years men have hoped that someone would come up with a reversal form of male birth control.
Now, according to Bloomberg, that day may be getting near.
Years of human trials on an injectable product that will zap sperm are coming to an end, and the results are promising.
A new birth control method for men has the potential to win as much as half the $10 billion market for female contraceptives worldwide and cut into the $3.2 billion of annual condom sales, businesses dominated by pharmaceutical giants Bayer AG, Pfizer Inc. and Merck & Co., according to estimates from the last major drug company to explore the area.
The technique has been developed in India, which would be the first market targeted.
The treatment, known as reversible inhibition of sperm under guidance, or RISUG, is reversed with a second shot that breaks down the gel, allowing sperm to reach the penis normally.